Patent · US Active

Compositions and methods for increasing expression of SCN2A

US11713463B2 · kind B2 · utility

0Cited by

2References

7Claims

0Family size

Assignee

THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH · AU

Inventors

Steven Petrou · Ponte Vedra, US
Eric G. Marcusson · San Francisco, US

Key dates

Filing date	Jan 17, 2019
Grant date	Aug 1, 2023
Priority date	—
Expiry date	Jan 17, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/34
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Described herein are compositions and methods that are used to increase the expression of SCN2A, which may be used to treat neurological or psychiatric disorders. Antisense oligonucleotides that target upstream open reading frames (uORFs) may be administered to prevent translation initiation from a uORF to increase expression from a primary ORF (pORF), thus increasing the levels of SCN2A protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.